Agoracom Blog Home

Posts Tagged ‘tsx’

#Coronavirus Scare Gives #Telehealth an Opening to Redefine Healthcare #Mhealth SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 6:12 PM on Thursday, March 12th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Coronavirus Scare Gives Telehealth an Opening to Redefine Healthcare

With the coronavirus threatening to become a pandemic, health systems and telehealth vendors see this as an opportunity to bring connected health to the forefront – and reshape the future of healthcare.

By Eric Wicklund

March 05, 2020 – As Congress votes on a funding package that includes Medicare waivers for some telehealth services and the Health Information and Management Systems Society (HIMSS) cancels its conference in Florida, healthcare providers across the country are looking at how connected care programs can be used to handle the coronavirus – also called COVID-19 – threat.

Most see the exercise as an extension of their preparations for flu season. Some see this as an opportunity to lobby for telehealth adoption across the board, saying a possible epidemic offers ample evidence of the value of telehealth and mHealth.

Defining Telehealth’s Value in a Changing Landscape

“COVID-19 is different because we do not know all the factors surrounding transmission and its effects on patients,” Jason Hallock, Chief Medical Officer for SOC Telemed, points out. â€œBecause coronavirus is new and there have been a significant number of deaths, the uncertainty surrounding that is scaring both patients and the general public. Our healthcare workers do not have all the answers yet. Telehealth providers are challenged to make recommendations when there are still many unknowns. Telemedicine can be useful to evaluate and reassure patients in alternative settings, and also can be used to help patients decide who needs to be seen in the hospital or an alternative setting like an urgent care.”

Hallock says telehealth can help by enabling healthcare providers to treat isolated patients, thus preventing the spread of what has so far been an extremely contagious virus.

In a Q&A with mHealthIntelligence, Peter Antall, MD, President and Chief Medical Officer for American Well, offered an in-depth take on how telehealth might be used.

READ MORE: Scripps Researchers Use mHealth Wearables to Track Flu Outbreaks

Q. Telehealth has long been seen as an ideal means of expediting care during flu outbreaks. How is the coronavirus scare different? Does this pose any unique challenges that telehealth can address?

A. The novel coronavirus, or COVID-19, is similar to influenza in how it is transmitted (airborne), how symptoms manifest themselves, and the fear it stirs among those individuals at risk. When evaluating patients through telehealth, we use similar methodology as that used for influenza, except that the current Centers for Disease Control and Prevention (CDC) recommendations call for risk stratification based on known exposure or travel to endemic areas and referral for testing for those at high risk or those who are sick enough to need hospital care. Also, unlike with influenza, there are no current specific treatments, like antivirals, for the coronavirus at this time. 

If local person-to-person spread expands to wide community spread, we expect care will need to evolve to a method that is quite similar to how we treat influenza today. Under those circumstances, we will likely begin diagnosing coronavirus-like illness (CLI) on a clinical basis, without testing. We would likely then only be expected to refer inpatients with CLI who need hospital care clinically, while those with milder symptoms will likely be treated and monitored at home so as to limit the spread of this disease and not overwhelm our healthcare facilities.

In this way, telehealth is an ideal venue for an outbreak like this. We can increase access to care. We can offer care that is commensurate with the acuity and nature of the symptoms and make referrals as needed. This helps with infection prevention and control and also allows patients to receive their care in the home without exposing themselves to further illness.

One other notable point is the potential for telehealth to help in providing routine care for other conditions and offset coronavirus fears in the . Patients have other healthcare needs unrelated to coronavirus, but many are afraid to go to healthcare settings for fear of catching disease. This has begun to result in a migration of patients to telehealth. For example, on February 25, we saw telehealth urgent care patient volume that was 11 percent higher than expected. Many patients are now sharing anecdotes indicating they were afraid to sit in a waiting room, so they used telehealth instead.

READ MORE: Using Telehealth Technology for Care Coordination During a Disaster

Q. Are there new tools or technologies available that can be useful in dealing with the coronavirus?

A. Telehealth itself is a tool in this fight. Keep in mind that there are many varieties of telehealth. It can be used to connect a doctor or other provider with a patient in the home via smartphones or tablets. It can also be used for provider (specialist)-to-provider consultations in remote areas, for example. Telehealth carts also exist in healthcare settings and can be used not only to import care, but also to limit healthcare workers’ exposure to the virus by using a cart in the isolation room.  We see patients primarily through live video interactions, but we also can fall back to informed telephone calls, synchronous chatting for therapy and asynchronous secure messaging for ongoing communications.

The use of symptom trackers and chatbots is another promising area for coronavirus response. These technologies allow algorithms to be created and adjusted as more is learned about the coronavirus. These bots interact with patients and can perform assessments, triage and ongoing support. The bots can even escalate an interaction to a telehealth encounter or refer the patient for in-person care.

Finally, home monitoring and medical tricorders are another promising approach to care. Traditional remote patient monitoring has established value for managing certain chronic conditions, but the next wave of home monitoring includes consumer devices like smartwatches (like the Apple Heart Study), home TVs, and home medical tricorders like Tytocare that can perform a remote examination. These tools aid clinicians and patients and provide more robust health data conveniently from the home setting. Providers can also use the data generated to better care for the patient or regularly monitor certain conditions.

Q. What must care providers know about telehealth before using it to deal with the coronavirus?

READ MORE: HHS Is Looking For mHealth Devices That Can Diagnose Influenza

A. Providers must know and understand their role in this or any other healthcare crisis. They should be well informed and trained to follow current CDC or World Health Organization guidelines. They should also understand that telehealth is a powerful tool for helping fight this outbreak. And they should know that telehealth is a safe way to treat and/or triage these patients. Whether the provider is a primary telehealth provider or is not using telehealth today, there is a real opportunity to participate and play a role in the response. 

Providers who have a brick-and-mortar practice should be encouraged to use telehealth as a triage tool. Providers also need to understand that during this time, patients with other non-respiratory conditions also need care. These patients should be afforded a safe way to access care without risk of infection. Telehealth is also a tool to aid in this process, as some patients are fearful of going to healthcare facilities right now. The office-based provider can likewise process other patients by practicing this way.

Q. What are the barriers or challenges associated with using telehealth to deal with the coronavirus scare?

A. Telehealth visits are typically sufficient to complete a robust initial assessment. This allow the provider to assign a risk category, make other diagnoses, or deem the patient as “worried well.” Some patients may require additional care, as most telehealth in the home lacks certain medical peripherals that might be needed. Other reasons for referral would include a high-risk patient who needs to be tested or a patient who requires escalation of care due to the severity of their illness. Telehealth visits are generally sufficient for screening patients, assigning a risk category, answering questions and recommending the next steps a patient should take.

The barriers to telehealth—such as instances when the patient and provider do not yet have a relationship—are easily overcome providers receive similar training around the use of telehealth and as longitudinal patient records become more available to guide care. Occasionally the lack of medical peripherals or the inability to touch the patient during an exam is a barrier, as some patients need hands on care (e.g., IV, procedures). We have policies that mitigate these problems in most cases. However, on occasion, a telehealth patient must be referred for in-person evaluation.

Q. Is there anything that the CDC or any other government agency can do to support telehealth adoption to deal with the coronavirus? 

A. It is useful for the CDC (and the WHO) to highlight the important role of telehealth in this outbreak because it certifies our role within the broader medical community and raises awareness about this tool.

It would be helpful if the CDC were to make specific recommendations to telehealth providers that relate to telehealth evaluation of the coronavirus and associated referrals, coding and monitoring. It would also be helpful if the CDC were to play a role in advocacy efforts focused on government reimbursement, particularly in this emergency situation. Efforts to increase consumer awareness about telehealth as a safe option for care also could prove essential. When this outbreak settles down, we would encourage the CDC and HHS to collaborate around coronavirus standards of care and preparedness so that patients can expect telehealth providers to be ideally prepared and well-coordinated for the next outbreak and so that we can offer high-quality care in this manner to all Americans.

We also believe that our public health system would benefit greatly from owning its own telehealth network infrastructure. This would allow the CDC to better scale up, solve for geography and improve surveillance. It would even allow its public health workers to use technology to monitor patients under quarantine in the home, saving themselves travel and limiting healthcare workers’ exposure.

Q.  What more can be done with telehealth in the future to plan for these types of outbreaks, or to perhaps address them before they become serious?

A. Much needs to be done throughout our country to better prepare. We need permanent leaders placed at the U.S. Department of Health and Human Services, the National Institutes for Health, the US Department of Homeland Security and other key areas, and we need to reinstate a pandemic-preparedness role at the National Security Council. We need to fund international efforts to improve screening and research for emerging diseases, and we need surveillance programs and good international coordination. We need to fund (not decrease funding) for our frontline groups, like the CDC, HHS and local public health services. These are our fighters, and we need them ready and funded properly as an outbreak like this is a national security issue. We need stockpiles of materials. Finally, we should be partnering with the pharmaceutical industry on affordable medications and vaccine research.

Our national telehealth operation today acts like an emergency alert system. We see cases or potential cases before they are reported. At American Well, our influenza activity indicator map is more accurate and more timely than that of the CDC. We already play a meaningful role in many disease states, including outbreaks. There are still many adoption and awareness challenges that exist when it comes to telehealth. Hopefully this unfortunate event will help consumers, providers and others start to more clearly see how they can and should use telehealth for future healthcare needs.

Another barrier that we continue to work on is that of reimbursement. Telehealth is a cost-effective way of receiving care, but it is still not always a covered benefit by insurance. Most commercial plans are reimbursing and there is increasing adoption in Medicare Advantage and Medicaid managed care. But there are still gaps, including a big gap in fee-for-service coverage for Medicare coverage in the home. Efforts at reform are underway (see the CONNECT Act), but more work needs to be done so that all Americans can take advantage of this amazing service.

Additionally, with coordination being so important during outbreaks like this, the simple step of integrating telehealth with other health information systems, such as EHRs or clinical-decision support, can make care more seamless and foster better care coordination. This would speed up access to critical care. Case in point: Consider a scenario where a patient consults with a physician over a telehealth network and displays symptoms of COVID-19 while presenting one or more correlating risk factors. The physician could easily document the experience, dispatch an alert to a local ED, and ensure precautions are taken by medical staff to usher this patient into a contained room or unit to begin testing and treatment. We’re working to ensure this type of communication is happening at all levels, but there’s still much room for improvement on this front. 

Health System Execs Respond to the Threat

In an op-ed prepared for the Alliance for Connected Care, Todd J. Vento, MD, MPH, Intermountain Healthcare’s Medical Director of Infectious Diseases Telehealth Service; Ethan Booker, MD, Medical Director of MedStar’s Telehealth Innovation Center; and Lawrence “Rusty” Hofmann, MD, Stanford Health’s Medical Director of Digital Health, made their pitch for telehealth:

“Telehealth, which has proven to be a very useful tool in addressing patient needs during flu season, will improve our collective ability to address COVID-19 if it hits on a larger scale. Telehealth offers several advantages over in-person care in the event of a pandemic.

One key advantage of telehealth is speed,” the three wrote. “Patients can access clinicians 24/7 without an appointment or physical trip to the doctor. Using telehealth, our providers in the Stanford Primary Care team, MedStar Health and Intermountain Healthcare have been actively evaluating and treating patients with influenza.  Current providers at Stanford Health estimate that almost 50% of patients are getting oseltamivir (Tamiflu).  Because there is no current, specific medication for Coronavirus, we must be able to advise patients of reasonable self-directed treatment and surveillance to keep them home. 

Keeping patients at home is a significant advantage of telehealth. In-home video visits limit community exposure by allowing patients to avoid contact with other patients in waiting rooms and direct contact with providers during the exam.  Our health systems have providers who are equipped to work from their own homes, significantly increasing the safety of providers and bolstering the workforce to respond to crisis.  Workforce readiness in a crisis that may include such dramatic measures as school and day care closures is a significant concern for health systems which may be strained to respond.  Health systems are also using telehealth to continue surveillance of patients already identified as at risk while keeping them at home.

Next, telehealth ensures that treatment in brick-and-mortar settings is reserved for high-need patients.  Moreover, with patients being seen in their own homes, providers and health systems will be able to triage and screen exponentially more patients with telehealth vs. an in-person visit.

Finally, telehealth allows patients who do not have access to infectious diseases (ID) specialists to access this specialized care from the small number of experts across the country. When Intermountain first offered ID telehealth consultation to rural systems throughout the west, one provider fielded 1,000 consultation requests in the first fifteen months. To date, the service has provided telehealth care to over 4,700 patients, 50 percent of whom are over 65 years old.

Each of these advantages illustrate how telehealth can thwart the spread of COVID-19 and stop it from overwhelming our already stretched medical system.”

The three health executive also urged lawmakers to take action to reduce barriers to telehealth that have kept adoption low:

“Congress must act to ensure that seniors – a particularly vulnerable population generally and for this virus in particular – are able to receive necessary triage and care through telehealth. 

Today, there are restrictions in Medicare that prevent providers outside of very rural areas from being paid for care provided through telehealth. As a result, many providers do not offer telehealth services to seniors. The lack of reimbursement creates a perverse incentive of encouraging patients to come for in-person care, which will only overwhelm our health system as well as augment the virus’s spread.

Congress must give the Secretary of Health and Human Services the ability to waive these restrictions in times of public health emergencies. As part of the bipartisan, bicameral CONNECT for Health Act, telehealth champions in Congress foresaw this need and drafted a provision that would give the Secretary the ability to waive telehealth restrictions just as he/she would waive Conditions of Participation, Stark Laws licensure, or other requirements when public health emergencies are declared.”

Source: https://mhealthintelligence.com/news/coronavirus-scare-gives-telehealth-an-opening-to-redefine-healthcare

#Edtech firms offer free access to colleges that is impacted by #Coronavirus – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 5:12 PM on Thursday, March 12th, 2020
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

Edtech firms offer free access to colleges that is impacted by Coronavirus

Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31

  • Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31.

By: Neha Alawadhi & Samreen Ahmad

Online education companies in India and globally are offering their paid programmmes to students — whether in school or pursuing higher education — free of cost because of the COVID-19 pandemic.

Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31.

“We’re going to make ‘Coursera for Campus’ offering freely available to any college or university in the world that is impacted by coronavirus, in the hope that they can rapidly allow students to start learning and ensure we have minimal impact from coronavirus on the student community,” said Leah Belsky, chief enterprise officer and senior vice-president, Coursera.

Coursera, founded by Stanford Professors Andrew Ng and Daphne Koller, has 48 million registered learners worldwide and offers courses, specialisations, degrees, and certificate programmes online.

The ‘Coursera for Campus’ offers job-relevant online education to students, alumni, faculty, and employees of firms like Mindtree, Tata Communications, Axis Bank, Infosys, Airtel, and Manipal Group.

Indian universities can continue teaching their students online without creating new infrastructure. Coursera’s existing ‘Coursera for Campus’ partners include Manipal Academy of Higher Education, UPES, Shiv Nadar University, KL University, NMIMS, and Pearl Academy.

In India, it has 5 million registered learners, and is adding over 100,000 learners per month.

Universities can sign up to provide their enrolled students with access to more than 3,800 courses and 400 specialisations from Coursera’s top university and industry partners.

Similarly, Indian education technology firms are also offering free classes and course material for students impacted by the novel coronavirus. On Wednesday, the World Health Organization declared COVID-19 a global pandemic.

Edtech firm Byju’s also said it will provide free access to its complete app to school students till the end of April.

Some Indian states like Kerala, Karnataka and New Delhi have already announced the closure of schools.

A UNESCO report states that the education of over 290 million students across 13 countries will be interrupted because of the COVID-19 pandemic.

Another edtech platform Unacademy said it will conduct close to 20,000 free live classes on its platform, across exam categories like UPSC, banking, railways and so on.

Unacademy claims it has 10,000 educators, 13 million learners, and subscriptions for over 30 exam categories.

Educational Initiatives, a 20-year old edtech company based out of Bengaluru is also offering 60 days free access of Mindspark to all students, so that the school closure due to COVID-19 does not impact their learning.

Mindspark is an artificial intelligence-powered specialised mathematics programme developed for children’s learning.

Similarly, edtech firm Toppr is going to provide free live classes to students in classes 5 to 12.

While it is yet to be seen how effective these measures will be, Coursera’s Belsky said the US education system invested in digitising after events like Hurricane Katrina, which forced school and college students to miss studies for months.

According to some estimates, in New Orleans alone, 110 of the 126 public schools were completely destroyed and students had to be moved to neighbouring states to complete their education.

Source: https://www.business-standard.com/article/education/edtech-firms-offer-free-access-to-colleges-that-is-impacted-by-coronavirus-120031201574_1.html

2 of Top 5 CBD Consuming Countries in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 3:00 PM on Thursday, March 12th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large
  • These countries are expected to account for virtually all of the legal marijuana sold globally in five years

Marijuana is one of the fastest growing industries on the planet. Legal weed sales have more than tripled between 2014 and 2018, and they’re on track to roughly quadruple between the $10.9 billion generated in licensed cannabis stores 2018 and the projected $40.6 billion in worldwide licensed store sales by 2024. That’s according to the 2019 “State of the Legal Cannabis Markets” report released earlier this year by Arcview Market Research and BDS Analytics.

Yet, what you might find intriguing about this rapid growth is that it’ll wind up being attributed to just a select few countries. Even though more than three dozen countries around the world have legalized medical marijuana, five countries are forecast by Arcview and BDS to account for $38.2 billion of this aforementioned $40.6 billion in licensed-store sales by 2024. Note, licensed-store sales doesn’t include general retailers selling cannabidiol (CBD) products, or cannabinoid-based drug developers selling pot-derived pharmaceuticals.

1. United States: $30.1 billion in cannabis spending by 2024

As should be no surprise, the U.S. projects as the leading marijuana market in the world by sales in 2024. In fact, the $30.1 billion in licensed-store revenue should comprise almost three-quarters of global licensed sales. According to Arcview and BDS, $9 billion of these sales are expected to come from the medical side of the equation, up from $4 billion in 2018, with the remaining $21.1 billion derived from recreational marijuana, up from $5.9 billion last year.

The thing about the U.S. is that cannabis stocks can still thrive even if the federal government doesn’t change its classification of marijuana from Schedule I. As long as Congress and the president continue to respect the right of states to make their own choices on cannabis, the industry could have plenty of runway.

One of the fastest early stage growers looks to be multistate dispensary operator Cresco Labs (OTC:CRLBF). Cresco, which holds the licenses to more than four dozen retail locations in 11 states, made a bold move in April when it announced an all-stock deal to acquire Origin House (OTC:ORHOF). Origin House is one of only a few companies to hold a cannabis distribution license in California, the state responsible for a quarter of all U.S. marijuana spending by 2024. Thus, Cresco Labs’ purchase of Origin House will give it access to more than 500 Californian dispensaries, and over 700 nationwide. Cresco and its vertically integrated peers appear well-positioned to take advantage of this huge growth opportunity.

2. Canada: $5.18 billion by 2024

Despite being the first industrialized country in the world to legalize recreational weed, Canada looks to take a distant second to the United States by 2024 in terms of sales. Arcview and BDS are projecting that $4.8 billion in sales will come from the recreational market by then, with the remainder made up of medical cannabis sales. It’s not uncommon for the medical industry to get cannibalized when adult-use marijuana is legalized, because it means patients no longer have to wait for a doctor’s approval and prescription to buy weed.

There’s a lot of competition in Canada right now, so it’s still unclear which company will be Canada’s kingpin. However, Aurora Cannabis (NYSE:ACB) is a relatively good bet to be near the top of the pack solely based on its production potential. Aurora is already leaps and bounds ahead of its next-closest competitors with an annual run-rate output of 150,000 kilos as of the end of March, and plans to be producing at least 625,000 kilos on a run-rate basis by the end of June 2020. With most of this production located in Canada, and the company sporting a number of large-scale grow farms, Aurora Cannabis should be able to take advantage of economies of scale to drive down its growing costs per gram.

Of course, the real near-term excitement revolves around the upcoming launch of derivative products (e.g,, edibles, vapes, topicals, concentrates, and infused beverages) by mid-December. Derivatives have much better margins and pricing power than dried cannabis flower, which is why Aurora Cannabis and its peers have been busy beefing up their product offerings over the past year in preparation for this upcoming launch date.

3. Germany: $1.35 billion by 2024

Even though Arcview and BDS are not expecting Germany to legalize recreational cannabis, the company’s highly permissive stance toward medical marijuana, and the fact that health insurers cover medical weed in the country, should allow sales to soar from $79 million in 2018 to $1.35 billion by 2024.

Interestingly enough, Canadian cannabis stocks were actually big-time winners of the German cultivation licensing process. Both Aurora Cannabis and Aphria (NYSE:APHA) were awarded licenses to grow cannabis in Germany. For its part, Aphria plans to have an 8,000-square-meter facility in Germany that’ll begin supplying the country with medical marijuana in the early part of 2020. In addition to growing cannabis, Aphria introduced CannRelief in Germany, which is a CBD-based nutraceutical and cosmetics product line. 

As for Aurora Cannabis, its approval to construct a growing facility will allow the company to supply the German market with 4,000 kilos of marijuana over four years, with shipments expected to commence October 2020. Of course, this production capacity is liable to be bumped up if patient demand merits it. 

4. Mexico: $1.02 billion by 2024

Arguably one of the oddest “legality” situations concerning marijuana right now is with Mexico. The nation’s Supreme Court has ruled five times since 2015 that imposing a ban on recreational cannabis is unconstitutional. That’s important, because when Mexico’s Supreme Court reaches five similar decisions on an issue, it becomes the standard throughout the country. Or, in layman’s terms, the Supreme Court has essentially affirmed the legality of recreational marijuana and is simply waiting for lawmakers in the country to hash out the details.

According to Arcview and BDS, Mexico will have legalized adult-use cannabis by 2024, although the ramp-up of legal sales could be slow. By 2024, recreational weed sales are only expected total $582 million, with an additional $441 million in medical spending, for a combined $1.02 billion. Mexico’s considerably larger population than Canada makes for an attractive market opportunity, but it’s unclear how well legal industries will fare with the noted presence of illicit producers.

One company that hasn’t been shy about its push into Mexico is Medical Marijuana, Inc. (OTC:MJNA), the very first publicly listed pot stock. Southern California-based Medical Marijuana was the first company to import CBD-rich oils into Mexico in 2016, giving it a head start on building important relationships with the country’s medical community. You’ll note that even with recreational legalization likely on the horizon, medical spending should continue to grow in Mexico. That gives Medical Marijuana and its RSHO-X hemp oil a real shot to continue penetrating the Mexico’s medical cannabis market. 

5. United Kingdom: $546.9 million by 2024

Although it may not be on track to tip the scales at $1 billion in sales by 2024, the U.K. is poised to be one of the fastest growing countries in the world based on cannabis spending. After only $9.9 million in medical spending last year, Britain is forecast for almost $547 million in medical marijuana revenue by 2024, representing a compound annual growth rate of 95.2%.

This sudden push to legalize and normalize medical pot use in the U.K. can be partially attributed to the success of GW Pharmaceuticals (NASDAQ:GWPH), the cannabinoid-based drug developer that had the U.S. Food and Drug Administration approve the very first cannabis-derived drug last year. GW Pharmaceuticals’ CBD-based oral solution known as Epidiolex dazzled in late-stage studies and wound up reducing seizure frequency for patients with two rare forms of childhood-onset epilepsy by 30% to 40%. Additionally, GW Pharmaceuticals’ Sativex, an oromucosal spray containing both CBD and tetrahydrocannabinol (THC), is approved in more than a dozen markets in Europe (but not the U.S.).

Britain’s citizens and its government have seen what the U.K.-based GW Pharmaceuticals can do with cannabinoids, and its government has been open to the possibility of expanding access to marijuana-based products for medical patients.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool recommends Origin House. The Motley Fool has a disclosure policy.

SOURCE: https://www.fool.com/investing/2019/09/08/5-countries-with-the-highest-cannabis-spending-by.aspx

Democracy Labs uses Datametrex AI $DM.ca #Nexalogy Tech to Study #Coronavirus Misinformation

Posted by AGORACOM-JC at 7:35 AM on Thursday, March 12th, 2020
  • Announce that Democracy Labs successfully used Nexalogy’s technology to monitor #covid19 and #coronavirus to identify misinformation campaigns and Fake News
  • Democracy Labs is a US based organization providing a hub for ongoing technology and creative innovation that serves progressive campaigns and organizations at the national, state, and local levels.

TORONTO, March 12, 2020 — Datametrex AI Limited (the “Company” or Datametrex”) (TSXV: DM) (FSE: D4G) is pleased to announce that Democracy Labs successfully used Nexalogy’s technology to monitor #covid19 and #coronavirus to identify misinformation campaigns and Fake News. Democracy Labs is a US based organization providing a hub for ongoing technology and creative innovation that serves progressive campaigns and organizations at the national, state, and local levels. In addition to misinformation about Covid-19 DemLabs has also used Nexalogy tech to examine Islamophobia against U.S. Representative Rashida Tlaib.

Key takeaways:

  • 450,000 tweets analyzed from March 1st through 4th using hashtag #covid19
  • Russia Today suggested that the U.S.A. primaries be cancelled and was promoted by BOTS

Results of these campaigns can be found by clicking the attached links:

https://insights.nexalogy.com/democracy-labs-uses-nexalogy-tech-to-study-coronavirus-misinformation-b88ea13c4bed
https://nexalogy.com/insights/keep-an-eye-on-trolls-activity-and-report-harassment-to-twitter/

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

For further information, please contact:

Jeff Stevens
Email: [email protected]Phone: 647-777-7974

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INTERVIEW: Datametrex $DM.ca – The Small Cap #A.I. Company Governments Use To Fight Fake News & Election Meddling

Posted by AGORACOM-JC at 5:01 PM on Wednesday, March 11th, 2020

Until now, investor participation in Artificial Intelligence has been the domain of mega companies and those funded by Silicon Valley.  Small cap investors can finally consider participating in the great future of A.I. through Datametrex AI (DM: TSXV) (Soon To Be Nexaology) who has achieved the following over the past few months:

  • Q3 Revenues Of $1.6 million,  an increase of 186%
  • 9 Month Revenues Of $2.56M an increase of 37%
  • Repeat Contracts Of $1M and $600,000 With Korean Giant LOTTE   
  • $954,000 Contract With Canadian Department of Defence To Fight Social Media Election Meddling
  • Participation In NATO Research Task Group On Social Media Threat Detection 

When a small cap Artificial Intelligence company is successfully deploying its technology with military and conglomerates, smart investors have to take a closer look.   That look can begin with our latest interview of Datametrex CEO, Marshall Gunter, who talks to us about the use of the Company’s Artificial Intelligence to discover and eliminate US Presidential election meddling.  The fake news isn’t just targeting candidates specifically, it also targets wedge issues such as abortion cases now before the US Supreme Court and even the Coronavirus.   Watch this interview on one of your favourite screens or hit play and listen to the audio as you drive. 

The most expensive #metals and where they are mined #Palladium SPONSOR: New Age Metals $NAM.ca $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 5:00 PM on Wednesday, March 11th, 2020

SPONSOR: New Age Metals Inc. The company owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces Inferred. Learn More.

The most expensive metals and where they are mined

  • Palladium is the most expensive of the four major precious metals – gold, silver and platinum being the others.
  • It is rarer than platinum, and is used in larger quantities for catalytic converters.
  • In the near-term, the demand for metals used in catalytic converters is expected to be steady, buoyed by growing automotive sales in Asia.

By Matthew Hall

Palladium

Rhodium’s little brother palladium also did well out of the Dieselgate scandal. After sales of diesel vehicles slumped and petrol alternatives came back into fashion, platinum – used primarily in catalytic converters for diesel vehicles – took a tumble, while petrol-friendly palladium rose.

Palladium is the most expensive of the four major precious metals – gold, silver and platinum being the others. It is rarer than platinum, and is used in larger quantities for catalytic converters. In the near-term, the demand for metals used in catalytic converters is expected to be steady, buoyed by growing automotive sales in Asia. However, the increased uptake of battery-electric vehicles – which do not use catalytic converters – could see palladium demand take a hit.

Russia00n mining company Nornickel is the top global palladium producer, pulling up 86 metric tons of the metal in 2019.

Rhodium

Relatively unknown to the layperson, rhodium is quietly one of the hottest trades right now, after a price surge of more than 30% this year. Rhodium previously peaked – and quickly crashed – in 2008 at more than $10,000 per troy ounce (ozt), but the metal is now trading above that 2008 high on the back of a swell in demand from the automotive industry.

Rhodium is used in catalytic converters, a part of vehicle exhaust systems that reduce toxic gas emissions and pollutants. According to S&P Global Platts, almost 80% of demand for rhodium and palladium comes from the global automotive industry. Fortunately for South Africa at least, around 80% of all rhodium is mined within its borders.

Part of the reason for the metal’s price leap is its rarity. Annual rhodium production sits at around 30 tonnes – to place that in context, gold miners annually dig up between 2,500 and 3,000 tonnes of the precious metal. Rhodium also benefitted from the Volkswagen emissions scandal, or Dieselgate, the 2015 emissions scandal that rocked the automotive industry. With major economies including China and India tightening emissions rules, platinum group metals (PGM) miners are anticipating good times ahead for rhodium.

Gold

Part durability, part tradition, gold is among the most versatile commodities. Primarily used in jewellery, but also having significant applications across electronics and aerospace due to its durability and conductivity, gold is, to put it plainly, everywhere.

Source: https://www.mining-technology.com/features/five-most-expensive-metals-and-where-they-are-mined/

Digital Learning #Edtech: Can it Solve the Access to Education Problem for Indian Students? – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 4:20 PM on Wednesday, March 11th, 2020
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

Digital Learning: Can it Solve the Access to Education Problem for Indian Students?

  • India is home to the largest youth population in the world.
  • As per recent government statistics, we have an estimated 430 million people under the age of 18.

Author: DQINDIA Online

Digital learning can help tackle existing problems in the education sector such as shortage of skilled teachers, lack of adequate teaching materials and so on.

India is home to the largest youth population in the world. As per recent government statistics, we have an estimated 430 million people under the age of 18. These young minds hold immense potential to build a strong future for themselves and the country. A potential that is often held to ransom by an education system marred by outmoded methods of teaching, disproportionate student to teacher ratio, a shortage of skilled teachers and lack of adequate teaching materials.

At a time when technology is transforming every other aspect of our existence, it is only natural that we turn to tech tools to disrupt the way we learn. A lack of access and resources emerges as a constant stumbling block in our youth’s pursuit of education – a problem that can be tackled by modernising the education system through digital learning. Here’s how:

Education beyond Boundaries

Digital content and e-learning can bring entire teaching modules to your doorstep through smart devices, making it possible for students to continue working toward completing their education even if they jump off the path of traditional learning. With a boom in cheaper data and devices, this mode of learning proves especially effective in pursuit of higher education or career-oriented skills. Access to online learning opportunities through remote classes, webinars and online academies can accord equal learning opportunities to students in Tier II and III cities as well as rural areas where skilled educators in one’s desired field of study may not be available.

Personalised Learning

The advent of deep data analytics, Artificial Intelligence and Machine Learning, personalised learning has become a tangible reality. These tech tools allow enable an identification of student goals – whether it is securing merit, landing jobs or simply amassing knowledge – and create educational content to suit these goals. This promotes a truly personalised approach toward learning. With the inclusion of edtech networks and multimedia in education, learning and teaching methods have evolved greatly in their methodology, style and content.

Learning on the Go

Gadgets are an integral part of the youth’s lifestyle today. From shopping to entertainment and social interactions, they seek everything on their finger tips and on the go. Their approach toward education and learning is no exception to this tendency. Digital learning allows them to consume educational content in a format they’re more comfortable in and at a place and setting of their choosing.

Affordability

The cost of higher education in India is steep. By comparison, specialised online course are far more affordable. If you factor in the costs of moving to and living in a big city for students from Tier II and III cities, small towns and rural areas, professional online courses don’t cost a fraction of brick-and-mortar set ups. It is for this reason that India is fast emerging as the second biggest market for MOOCs or open online courses, after the US. This new educational revolution presents great opportunity to help the youth access high-quality education and training, at affordable price points, from the comfort of their homes.

Job Readiness

The higher education in India essentially revolves around securing a stable – ideally, well-paying – job. With easy access to e-learning platforms and digital content, students can access the right kind of content in a format fit for their preferred mode of consumption and be better equipped to meet this goal. For instance, the same curriculum can be easily tweaked to suit academic and competitive purposes in a cost-effective manner in the e-book format.

Future-Ready Education

The world around us is changing at a lightning fast pace, thanks to the constant eruptions of the technology front. Sadly, most of the traditional forums of learning – be it schools, colleges or universities – find themselves lagging behind when it comes to tailoring the course content as per the changing demands of the times we live in. Besides, overhauling entire course curriculums can often a slow, time-consuming process. In such a scenario, professionally tailored online courses can be a bankable alternative in amassing skills training that contributes to employability and is in line with the learners’ interests.

It is undisputable that the future of education will be defined by digital content and learning. Students in India can ride this wave to tide over the inherent flaws in our education system and set themselves up for success in their chosen profession.

Source: https://www.dqindia.com/digital-learning-can-solve-access-education-problem-indian-students/

CLIENT FEATURE: Mota Ventures MOTA.ca – $29,000,000 in Combined Sales with 2019 EBITDA of Approximately 12.5% $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:53 PM on Wednesday, March 11th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

MOTA:CSE

RECENT HIGHLIGHTS

  • Direct to Consumer E-commerce retailer
  • Revenue generating, EBIDTA positive
  • Formalized Joint Venture With Bevcanna Enterprises: Read More
    • Will share equal ownership in the Joint Venture and will be jointly responsible for developing and funding its operations
    • Company will provide manufacturing, marketing and distribution infrastructure in the European market.
    • Parties have determined an initial product launch and will provide further details on specific regions and timing once finalize
  • Announced Collaboration for Sativida US Expansion Read More 
    • Unified Funding will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing
    • Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico
  • Entered into Licensing Agreement with Phenome One Read More
    • A privately held full-service live genetic and seed preservation cannabis company.
    • Mota will have full access to Canada’s largest live genetic cannabis library with over 350 cultivars
    • Mota will have the right to propagate, cultivate, harvest and process a minimum of 10 selected cultivars

2 World Class Brands

#1. FIRST CLASS CBD

ONE OF THE LARGEST US BASED ONLINE RETAILERS OF CBD PRODUCTS

HIGHLIGHTS:

  • Leader in online CBD sales in North America
  • Crop to package model: US grown CBD hemp
  • Acquired at a 1.5 times revenue valuation
  • Current customer base 142,000 customers -with additional leads of over 424,000 potential new customers
  • 2019 Sales of $19.2M USD/ EBITDA of 2.7M USD

  #2. SATIVIDA

ONLINE DIRECT TO CONSUMER RETAILER OF A VAST RANGE OF ORGANICE CBD OILS AND COSMETICS

HIGHLIGHTS:

  • Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
  • Number one search-ranked online retailer in Spain and Mexico
  • Award winning product line known for its minimal heavy metal content and accurate CBD levels
  • 100% organic products

 FIND OUT MORE!

Hub on Agoracom

FULL DISCLOSURE: Mota Ventures. is an advertising client of AGORA Internet Relations Corp.

Hollister Biosciences $HOLL.ca Enters Letter of Intent to Acquire Alphamind $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca Brands

Posted by AGORACOM-JC at 7:02 AM on Wednesday, March 11th, 2020
  • Entered into a letter of intent on March 9th, 2020 to acquire Alphamind Brands
  • Company developing legal mushroom based natural health products and conducting R&D in conjunction with accredited universities to develop psilocybin based compounds for drug development
  • All stock purchase price is anticipated to be CDN$ 1,200,000 with such payment to be made in Hollister common stock

VANCOUVER, March 11, 2020 – Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company has entered into a letter of intent (the “LOI“) on March 9th, 2020 to acquire Alphamind Brands ( “Alphamind“), a company developing legal mushroom based natural health products and conducting R&D in conjunction with accredited universities to develop psilocybin based compounds for drug development.

The all stock purchase price is anticipated to be CDN$ 1,200,000 with such payment to be made in Hollister common stock. The stock price will be determined based on the greater of the 14-day VWAP (Volume Weighted Average Price) subsequent to announcing the transaction and $0.20.  The acquisition is subject to normal course due diligence. 

“We are very pleased to have entered into an LOI to complete this very exciting acquisition”, shared Carl Saling, Founder and CEO of Hollister Biosciences Inc.  “It is a fundamental value of our company to improve the overall health and performance of our customers through our high-quality products and the health benefits associated with medicinal mushrooms are tremendous.  Not to mention, it is our continual objective to broaden our product scope and Alphamind, with its experienced management team, is a perfect foothold for us in the fast-growing market for medicinal mushrooms and complements our existing cannabis and hemp-based product offering.”

“I think we have found a great partner in Hollister”, shared Robert Birmingham, CEO of Alphamind Brands.  “We have medicinal mushroom based product SKU’s ready to ship and R&D is underway to develop an exciting IP portfolio surrounding psilocybin based pharmaceutical treatments. Being under the Hollister umbrella will allow us to access additional markets and leverage their existing manufacturing and distribution infrastructure and will be a fundamental part of the future growth of our business.”

In association with the arm’s length transaction, Hollister will not be assuming any long-term debt and there is no change in Management, or the Board of Directors of Hollister being contemplated at this time.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a diversified cannabis company with multiple, high-quality products now carried in 220 of Indus Holdings (CSE: INDS), Hollister’s exclusive distribution partner’s 600 dispensaries. This level of penetration is expected to grow as the Company accelerates its seed to shelf, high margin business and product development model.

Capitalizing on this success, Hollister’s vision is to become the sought-after premium brand portfolio of innovative, high quality cannabis across multiple states and hemp products nationwide.

Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California, the birthplace of the “American Biker” from which we embrace the outlaw roots of Hollister to drive our Company fearlessly down the road of success.

Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll ranked as California’s #1 hash infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.

Website: www.hollistercannabisco.com 

About Alphamind Brands

Alphamind Brands is a Canada and US based growth stage company developing a portfolio of legal mushroom based natural health products as well as conducting R&D initiatives, led by Dr. Nikos Apostolopoulos, to explore psilocybin based pharmaceutical treatments.  The company’s “ready to ship” product SKU’s include cordyceps, lion’s mane, chaga and reishi mushroom based: liquid cordyceps, concentrated mushroom powder, tea, chocolate.  The company’s product SKU’s under development include syrups, elixirs, cold beverages and nasal spray.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-enters-letter-of-intent-to-acquire-alphamind-brands-301021154.html

SOURCE Hollister Biosciences Inc.

CBD Market on Course to Grow 400% in Europe Alone SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:08 PM on Tuesday, March 10th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large
  • Over the next five years, the global CBD market is expected to accelerate to $23.6bn, according to Grand View Research and Europe’s CBD market is set to grow by 400%.

The growth of the CBD market in Europe is thanks to the growing adoption of CBD infused products in industries such as pharmaceuticals, personal care, cosmetics, nutraceuticals, along with medical applications.

CBD is seeing monumental demand in Europe. In Europe alone, the market is on course to grow 400% over the next four years, according to the Brightfield Group.

According to New Frontier Data‘s EU CBD Consumer Report: 2019 Overview, 46% of Europeans view CBD favourably, and up to 77% of surveyed respondents also believe CBD should be accessible in some way.

CBD opportunities

The legal cannabis industry continues to expand around the world with major contribution to the market coming from continuous legislative victories in North America and Europe. In particular, legalisation of medical cannabis, and decriminalisation in some countries, has led to a significant decrease in black-market activity, as people are shifting to legally purchasing cannabis for medical as well as recreational use.

In the meantime, local governments reap the benefits through taxation. For instance, the state of California had collected a total of $345.2m in tax revenue from legal cannabis during the first year of regulated sales in 2018. Revenue generated from these taxes encouraged the local governments to fund several development programmes for education and infrastructure.

Medical cannabis

Overall, data by Grand View Research indicates that the medical segment held the dominant revenue share of the cannabis market, accounting for 71.0% in 2019. Medical use of cannabis is strictly categorised as a medicine prescribed by a physician and the distribution of these medicines is regulated by the government. However, by 2027, adult-use is expected to become the fastest-growing segment with adult-use products ranging from a highly potent concentrate to a simple food ingredient.

In recent years, CBD products have swiftly emerged and the growth of the CBD market is largely attributed to various medical applications that are associated with the products. For example, full-spectrum CBD oil is considered to be a great source of Omega 3 and Omega 6; Omega 3 plays a vital role in creating hormones that regulate inflammation as well as contractions and relaxation of arteries.

SOURCE: https://www.healtheuropa.eu/cbd-market-to-grow-400-in-europe/98021/